Drug developers have tried for decades without success to develop treatments for sepsis, a brutal infection that can lead to organ failure. Now a leading immunotherapy company is taking the novel approach of using cutting-edge cancer drugs to try to beat back the deadly infection of the blood.

Sepsis is implicated in up to half of hospital deaths, amounting to hundreds of thousands of deaths in the US per year. Doctors can use antibiotics to help control septic infections, but they don’t work in many cases. And when the immune system ramps up in its attempt to overcome the bacteria, it often inflicts collateral damage on the heart, kidney, lungs, liver, and brain.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy